Caixia Li

6PUBLICATIONS
89CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classifiedBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 22, 2026
Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.

|Jun 26, 2026
Safety and Efficacy of Plerixafor in Poor Mobilizers With Lymphoma: A Multicenter, Prospective, Single-Arm Study.

|Apr 14, 2026
Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-T alone in relapsed/refractory large B-cell lymphoma.

Jiaqi Li, Shanglong Feng, Sixun Jia

|Feb 26, 2025
Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with De Novo Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial.

Xiang Zhang, Yue Han, Huiying Qiu

|Sep 30, 2023
Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma.

Ying Zhang, Hongzhi Geng, Liangyu Zeng

|Sep 01, 2022
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.

Jing Deng, Aneel Paulus, Douglas D Fang

Pageof 1

Frequent Collaborators

3 joint publications

Depei Wu

1 joint publications

Jing Deng

1 joint publications

Aneel Paulus

1 joint publications

Douglas D Fang